Legal Representation
Attorney
Sandra Lex
USPTO Deadlines
Next Deadline
1596 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2023-12-05)
Due Date
December 05, 2029
Grace Period Ends
June 05, 2030
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
35 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Mar 26, 2024 | FINO | P | FINAL DECISION TRANSACTION PROCESSED BY IB | Loading... |
| Mar 6, 2024 | FICS | P | FINAL DISPOSITION NOTICE SENT TO IB | Loading... |
| Mar 5, 2024 | FICR | P | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | Loading... |
| Mar 5, 2024 | FIMP | P | FINAL DISPOSITION PROCESSED | Loading... |
| Dec 5, 2023 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
| Dec 5, 2023 | NRCC | E | NOTICE OF REGISTRATION CONFIRMATION EMAILED | Loading... |
| Sep 19, 2023 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Sep 19, 2023 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Sep 17, 2023 | GPNX | P | NOTIFICATION PROCESSED BY IB | Loading... |
| Aug 30, 2023 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Aug 30, 2023 | OP2R | P | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | Loading... |
| Aug 30, 2023 | OPNS | P | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | Loading... |
| Aug 17, 2023 | CNEA | R | EXAMINERS AMENDMENT -WRITTEN | Loading... |
| Aug 17, 2023 | GNEA | O | EXAMINERS AMENDMENT E-MAILED | Loading... |
| Aug 17, 2023 | GNEN | O | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | Loading... |
| Aug 17, 2023 | XAEC | I | EXAMINER'S AMENDMENT ENTERED | Loading... |
| Aug 17, 2023 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| May 9, 2023 | OPNX | P | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | Loading... |
| Apr 19, 2023 | OPNR | P | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | Loading... |
| Apr 19, 2023 | OPNS | P | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | Loading... |
| Jan 31, 2023 | CNFR | R | FINAL REFUSAL WRITTEN | Loading... |
| Jan 31, 2023 | GNFR | O | FINAL REFUSAL E-MAILED | Loading... |
| Jan 31, 2023 | GNFN | O | NOTIFICATION OF FINAL REFUSAL EMAILED | Loading... |
| Dec 29, 2022 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Dec 29, 2022 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Dec 29, 2022 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Jul 26, 2022 | RFNT | P | REFUSAL PROCESSED BY IB | Loading... |
| Jul 2, 2022 | RFRR | P | REFUSAL PROCESSED BY MPU | Loading... |
| Jul 2, 2022 | RFCS | P | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | Loading... |
| Jun 25, 2022 | RFCR | E | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | Loading... |
| Jun 24, 2022 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Jun 21, 2022 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Nov 23, 2021 | MAFR | O | APPLICATION FILING RECEIPT MAILED | Loading... |
| Nov 19, 2021 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Nov 18, 2021 | REPR | M | SN ASSIGNED FOR SECT 66A APPL FROM IB | Loading... |
Detailed Classifications
Class 005
Pharmaceutical products and medical products, namely blood for medical purposes; medical preparations, namely blood for medical purposes; pharmaceutical proteins and medical protein preparations made from human blood, blood plasma and blood serum, namely, immunoglobulin preparations, immunoglobulins and hyperimmunoglobulins, all being pharmaceutical preparations for preventing and treating of immune system related diseases and disorders, neurological diseases and disorders, cancer, infections; pharmaceutical preparations for immunology, neurology, intensive medicine, transplantation medicine, oncology, namely pharmaceutical preparations for the prevention and treatment of immune system-related diseases and disorders, neurological diseases and disorders, cancer, and infections; pharmaceutical preparations for preventing and treating viral diseases, diseases of the immune system, autoimmune diseases and oncological diseases; immunosuppressant, immunomodulatory, anti-inflammatory, antiallergic, hyposensitizing and detoxifying or toxin-neutralizing medicines, namely pharmaceutical preparations for treatment of immune-related diseases and disorders, for treatment of allergies, and for treatment of infections
First Use Anywhere:
0
First Use in Commerce:
0
Classification
International Classes
005